612 related articles for article (PubMed ID: 16270213)
1. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
[TBL] [Abstract][Full Text] [Related]
3. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
[TBL] [Abstract][Full Text] [Related]
5. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
[TBL] [Abstract][Full Text] [Related]
6. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Raffoux E; Chaibi P; Dombret H; Degos L
Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
[TBL] [Abstract][Full Text] [Related]
8. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
Bellos F; Mahlknecht U
Onkologie; 2008 Nov; 31(11):629-33. PubMed ID: 19145098
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid for the treatment of myeloid malignancies.
Kuendgen A; Gattermann N
Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
[TBL] [Abstract][Full Text] [Related]
11. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
[TBL] [Abstract][Full Text] [Related]
13. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
Kuendgen A; Strupp C; Aivado M; Bernhardt A; Hildebrandt B; Haas R; Germing U; Gattermann N
Blood; 2004 Sep; 104(5):1266-9. PubMed ID: 15155466
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.
Di Febo A; Laurenti L; Falcucci P; Tosti ME; Fianchi L; Pagano L; Leone G
Am J Ther; 2007; 14(4):351-5. PubMed ID: 17667210
[TBL] [Abstract][Full Text] [Related]
16. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
Ryningen A; Stapnes C; Lassalle P; Corbascio M; Gjertsen BT; Bruserud O
Leuk Res; 2009 Jun; 33(6):779-87. PubMed ID: 19007987
[TBL] [Abstract][Full Text] [Related]
17. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
Knipp S; Hildebrand B; Kündgen A; Giagounidis A; Kobbe G; Haas R; Aul C; Gattermann N; Germing U
Cancer; 2007 Jul; 110(2):345-52. PubMed ID: 17559141
[TBL] [Abstract][Full Text] [Related]
19. [Low-dose chemotherapy].
Ogata K; Yamada T; Dan K
Rinsho Ketsueki; 1996 Sep; 37(9):777-81. PubMed ID: 8914461
[TBL] [Abstract][Full Text] [Related]
20. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
Ferrero D; Campa E; Dellacasa C; Campana S; Foli C; Boccadoro M
Haematologica; 2004 May; 89(5):619-20. PubMed ID: 15136232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
